Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug ZW191 targets Hard-to-Treat cancers in early trial

NCT ID NCT06555744

Ongoing Disease control Sponsor: Zymeworks BC Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, find the right dose, and see if it shrinks tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer neoplasm non-small cell lung carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Clínica Universidad de Navarra

    Madrid, 28027, Spain

  • Curie Oncology

    Singapore, 217562, Singapore

  • Fundacion Instituto Valenciano de Oncologia (IVO)

    Valencia, 46009, Spain

  • Gangnam Severance Hospital

    Seoul, 6273, South Korea

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, 14004, Spain

  • Linear Clinical Research

    Nedlands, WA 6009, Australia

  • NEXT Oncology

    San Antonio, Texas, 78229, United States

  • NEXT Oncology Madrid

    Madrid, 28223, Spain

  • NEXT Virginia

    Fairfax, Virginia, 22031, United States

  • National Cancer Center

    Goyang-si, 10408, South Korea

  • National Cancer Center Hospital

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    Kashiwa-shi, 277-8577, Japan

  • National Cancer Centre Singapore

    Singapore, 168583, Singapore

  • National University Health System (NUHS) - National University Cancer Institute Singapore (NCIS)

    Singapore, 119228, Singapore

  • Royal North Shore Hospital Northern Sydney Cancer Centre

    St Leonards, NSW 2065, Australia

  • Saitama Medical University International Medical Center

    Saitama, 350-1298, Japan

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

  • The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

    Columbus, Ohio, 43210, United States

  • The Cancer Institute Hospital of JFCR

    Tokyo, 135-8550, Japan

  • Yale University

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.